Clinical Trials in Boston

Showing 10881-10900 of 15,299 trials

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

NCT02118987

This research study is evaluating a drug called omalizumab (brand name 'Xolair') as a potential treatment to be used in conjunction with drug desensitization to prevent reactions from recurring and allowing the participant to be treated with the chemotherapy the participant's oncologist prefers to give.

Drug Allergy

Dana-Farber Cancer Institute5 participantsStarted Jul 2014

Boston, Massachusetts, United States • Boston, Massachusetts, United States

COMPLETEDPhase 3< 1 mile

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

NCT00088179

During a heart bypass procedure, a substance called "complement" is activated by the body. This "complement activation" causes an inflammatory response that can lead to side affects such as chest pain, heart attacks, stroke, heart failure, or death. The purpose of this study is to find out if the study drug (pexelizumab), that blocks "complement activation," can reduce such side effects and be given safely to patients requiring the bypass procedure with the use of the heart-lung machine.

Coronary Artery Disease

Alexion Pharmaceuticals, Inc.4,000 participantsStarted Jul 2004

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +185 more locations

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Find Trials by Condition in Boston

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis

Extension Study of Gelesis100 on Body Weight

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Bortezomib Plus Rituximab for EBV+ PTLD

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Prenatal Screening for Down Syndrome With DNAFirst

A Study of LY2801653 in Advanced Cancer

Optimize RV Follow-up Selective Site Pacing Clinical Trial

SISTERS: Spasticity In Stroke Study - Randomized Study

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer